Abstract
PURPOSE:
This phase I trial evaluated intraperitoneal (IP) pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
EXPERIMENTAL DESIGN:
Dose
escalation of d1 IP pemetrexed accrued 3 patients to each of 5 dose
levels (60mg/m2 to 1000mg/m2), along with d2 IP cisplatin (75mg/m2), and
d8 IP paclitaxel (60mg/m2). The goals were to determine maximum
tolerated dose (MTD), 18-month progression-free survival (PFS), and
pharmacokinetics (PK) of IP pemetrexed.
RESULTS:
Cycles,
given every 21d, had an 80% 6-cycle completion rate. There was minimal
grade 3 toxicity in the first 4 dose levels and remarkably an almost
complete absence of peripheral neuropathy and alopecia. At the highest
dose level, 2 of 3 patients experienced greater than or equal to grade 3
and dose-limiting toxicity (DLT)(hematologic, infection,
gastrointestinal). There was a PK advantage for IP pemetrexed with a
IP:plasma area under the concentration-time-curve ratio of 13-fold.
Neither analysis of PK nor homocysteine levels explains the unexpected
severity of toxicity in those 2 patients. Based on plasma C24 h levels,
the 42 cycles at greater than or equal to 500mg/m2 IP pemetrexed without
DLT, the MTD appears to be 500mg/m2. Median PFS is 30.1 months;
18-month PFS is 78.6% (median follow-up 22.4 months).
CONCLUSIONS:
This
IP only regimen in
front-line ovarian cancer is feasible with PFS in
line with recent literature. We suggest phase II trials of this regimen
in this population with IP pemetrexed at 500mg/m2. The favorable
toxicity profile at doses less than 1000mg/m2, which
needs to be
confirmed, appears to compare well with standard combination
intravenous/IP platinum/taxane chemotherapy in this disease.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.